502 related articles for article (PubMed ID: 15916052)
1. Prevalence of strongyloides in Northern Thailand and treatment with ivermectin vs albendazole.
Nontasut P; Muennoo C; Sa-nguankiat S; Fongsri S; Vichit A
Southeast Asian J Trop Med Public Health; 2005 Mar; 36(2):442-4. PubMed ID: 15916052
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of a single-dose veterinary preparation of ivermectin versus 7-day high-dose albendazole for chronic strongyloidiasis.
Suputtamongkol Y; Kungpanichkul N; Silpasakorn S; Beeching NJ
Int J Antimicrob Agents; 2008 Jan; 31(1):46-9. PubMed ID: 18023151
[TBL] [Abstract][Full Text] [Related]
3. Disseminated strongyloidiasis successfully treated with extended duration ivermectin combined with albendazole: a case report of intractable strongyloidiasis.
Pornsuriyasak P; Niticharoenpong K; Sakapibunnan A
Southeast Asian J Trop Med Public Health; 2004 Sep; 35(3):531-4. PubMed ID: 15689061
[TBL] [Abstract][Full Text] [Related]
4. A comparative trial of a single-dose ivermectin versus three days of albendazole for treatment of Strongyloides stercoralis and other soil-transmitted helminth infections in children.
Marti H; Haji HJ; Savioli L; Chwaya HM; Mgeni AF; Ameir JS; Hatz C
Am J Trop Med Hyg; 1996 Nov; 55(5):477-81. PubMed ID: 8940976
[TBL] [Abstract][Full Text] [Related]
5. Randomized comparative trial of two high-dose albendazole regimens for uncomplicated human strongyloidiasis.
Singthong S; Intapan PM; Wongsaroji T; Maleewong W
Southeast Asian J Trop Med Public Health; 2006; 37 Suppl 3():32-4. PubMed ID: 17547048
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of single and double doses of ivermectin versus 7-day high dose albendazole for chronic strongyloidiasis.
Suputtamongkol Y; Premasathian N; Bhumimuang K; Waywa D; Nilganuwong S; Karuphong E; Anekthananon T; Wanachiwanawin D; Silpasakorn S
PLoS Negl Trop Dis; 2011 May; 5(5):e1044. PubMed ID: 21572981
[TBL] [Abstract][Full Text] [Related]
7. [Efficacy of ivermectin in the treatment of children parasitized by Strongyloides stercoralis].
Ordóñez LE; Angulo ES
Biomedica; 2004 Mar; 24(1):33-41. PubMed ID: 15239599
[TBL] [Abstract][Full Text] [Related]
8. Comparison of ivermectin and albendazole treatment for gnathostomiasis.
Nontasut P; Bussaratid V; Chullawichit S; Charoensook N; Visetsuk K
Southeast Asian J Trop Med Public Health; 2000 Jun; 31(2):374-7. PubMed ID: 11127342
[TBL] [Abstract][Full Text] [Related]
9. Persistent eosinophilia and Strongyloides infection in Montagnard refugees after presumptive albendazole therapy.
Goswami ND; Shah JJ; Corey GR; Stout JE
Am J Trop Med Hyg; 2009 Aug; 81(2):302-4. PubMed ID: 19635888
[TBL] [Abstract][Full Text] [Related]
10. Utility of serological follow-up of chronic strongyloidiasis after anthelminthic chemotherapy.
Page WA; Dempsey K; McCarthy JS
Trans R Soc Trop Med Hyg; 2006 Nov; 100(11):1056-62. PubMed ID: 16551471
[TBL] [Abstract][Full Text] [Related]
11. Ivermectin versus albendazole or thiabendazole for Strongyloides stercoralis infection.
Henriquez-Camacho C; Gotuzzo E; Echevarria J; White AC; Terashima A; Samalvides F; Pérez-Molina JA; Plana MN
Cochrane Database Syst Rev; 2016 Jan; 2016(1):CD007745. PubMed ID: 26778150
[TBL] [Abstract][Full Text] [Related]
12. Risk factors for strongyloidiasis hyperinfection and clinical outcomes.
Asdamongkol N; Pornsuriyasak P; Sungkanuparph S
Southeast Asian J Trop Med Public Health; 2006 Sep; 37(5):875-84. PubMed ID: 17333728
[TBL] [Abstract][Full Text] [Related]
13. Comparative studies on the efficacy of three anthelminthics on treatment of human strongyloidiasis in Okinawa, Japan.
Toma H; Sato Y; Shiroma Y; Kobayashi J; Shimabukuro I; Takara M
Southeast Asian J Trop Med Public Health; 2000 Mar; 31(1):147-51. PubMed ID: 11023084
[TBL] [Abstract][Full Text] [Related]
14. Double-dose ivermectin vs albendazole for the treatment of gnathostomiasis.
Nontasut P; Claesson BA; Dekumyoy P; Pakdee W; Chullawichit S
Southeast Asian J Trop Med Public Health; 2005 May; 36(3):650-2. PubMed ID: 16124432
[TBL] [Abstract][Full Text] [Related]
15. Strongyloides stercoralis, the hidden worm. Epidemiological and clinical characteristics of 70 cases diagnosed in the North Metropolitan Area of Barcelona, Spain, 2003-2012.
Valerio L; Roure S; Fernández-Rivas G; Basile L; Martínez-Cuevas O; Ballesteros ÁL; Ramos X; Sabrià M;
Trans R Soc Trop Med Hyg; 2013 Aug; 107(8):465-70. PubMed ID: 23783760
[TBL] [Abstract][Full Text] [Related]
16. Hyperinfection strongyloidiasis in a liver transplant recipient treated with parenteral ivermectin.
Lichtenberger P; Rosa-Cunha I; Morris M; Nishida S; Akpinar E; Gaitan J; Tzakis A; Doblecki-Lewis S
Transpl Infect Dis; 2009 Apr; 11(2):137-42. PubMed ID: 19144097
[TBL] [Abstract][Full Text] [Related]
17. Community control studies on Strongyloides infection in a model island of Okinawa, Japan.
Toma H; Shimabukuro I; Kobayashi J; Tasaki T; Takara M; Sato Y
Southeast Asian J Trop Med Public Health; 2000 Jun; 31(2):383-7. PubMed ID: 11127344
[TBL] [Abstract][Full Text] [Related]
18. Subcutaneous ivermectin as a safe salvage therapy in Strongyloides stercoralis hyperinfection syndrome: a case report.
Pacanowski J; Santos MD; Roux A; LE Maignan C; Guillot J; Lavarde V; Cornet M
Am J Trop Med Hyg; 2005 Jul; 73(1):122-4. PubMed ID: 16014846
[TBL] [Abstract][Full Text] [Related]
19. Albendazole in the treatment of strongyloidiasis.
Pungpak S; Bunnag D; Chindanond D; Radmoyos B
Southeast Asian J Trop Med Public Health; 1987 Jun; 18(2):207-10. PubMed ID: 3672182
[TBL] [Abstract][Full Text] [Related]
20. Strongyloidiasis: a review of the evidence for Australian practitioners.
Johnston FH; Morris PS; Speare R; McCarthy J; Currie B; Ewald D; Page W; Dempsey K
Aust J Rural Health; 2005 Aug; 13(4):247-54. PubMed ID: 16048468
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
